HealthCare Global Enterprises Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript HealthCare Global Enterprises Ltd filed with BSE on 10 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
HCG reported Q1 FY27 revenue of INR6,951 million, up approximately 13% year-on-year, driven by an 11% increase in patient volumes and 2% ARPP growth. Adjusted EBITDA rose 20% year-on-year to INR1,339 million with margins improving to 19.4% from 18.2% in Q1 FY26. Management discussed the North Bangalore hospital ramp-up, bed capacity expansion plans, the completed Fertility business divestment, and use of rights issue proceeds for debt repayment and the Vizag stake increase.
1 statement from this call is not shown because its supporting quote could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Revenue: INR6,951 million (Q1 FY27)
p. 3
“During the quarter, HCG delivered revenue of INR6,951 million, representing approximately 13% year-on-year growth.”
Manish Mattoo, page 3 of the filed PDF · View the filing
North Bangalore hospital revenue: INR67 million (Q1 FY27)
p. 3
“Our newly operational North Bangalore hospital, which commenced operations in May '26, contributed INR67 million during this very first quarter.”
Manish Mattoo, page 3 of the filed PDF · View the filing
Patient volume growth: 11% (Q1 FY27)
p. 3
“Revenue growth during the quarter was primarily driven by an 11% increase in patient volumes.”
Manish Mattoo, page 3 of the filed PDF · View the filing
ARPP growth: 2% (Q1 FY27)
p. 3
“ARPP grew by 2%.”
Manish Mattoo, page 3 of the filed PDF · View the filing
Non-institutional business revenue growth: 17% (Q1 FY27 year-on-year)
p. 3
“During the quarter, non-institutional business revenue grew by 17% year-on-year.”
Manish Mattoo, page 3 of the filed PDF · View the filing
Non-institutional revenue contribution: 69% (Q1 FY27)
p. 3
“our payor mix improved with non-institutional contribution increasing from 67% in Q1 FY'26 to 69% in Q1 FY27”
Manish Mattoo, page 3 of the filed PDF · View the filing
Reported EBITDA: INR1,223 million (Q1 FY27)
p. 3
“On the profitability front, reported EBITDA for the quarter stood at INR1,223 million, excluding losses from North Bangalore and one-off costs.”
Manish Mattoo, page 3 of the filed PDF · View the filing
Adjusted EBITDA: INR1,339 million (Q1 FY27)
p. 3
“Adjusted EBITDA increased by 20% year-on-year to INR1,339 million, with EBITDA margins improving to 19.4% from 18.2% in Q1 FY26.”
Manish Mattoo, page 3 of the filed PDF · View the filing
South cluster revenue growth: 16% (Q1 FY27 year-on-year)
p. 3
“The South cluster delivered another strong quarter with revenue growing approximately 16% year-on-year, supported by healthy growth in both patient volumes and realizations.”
Manish Mattoo, page 3 of the filed PDF · View the filing
West cluster revenue growth: 9% (Q1 FY27)
p. 3
“The West cluster reported a growth of 9%, led by the Maharashtra region, which grew by over 14%, while growth in the Gujarat remained relatively moderate during the quarter.”
Manish Mattoo, page 3 of the filed PDF · View the filing
East cluster revenue growth: 22% (Q1 FY27)
p. 4
“East cluster delivered strong 22% revenue growth during this quarter, driven by robust volume growth across the region.”
Manish Mattoo, page 4 of the filed PDF · View the filing
Operational beds added: 121 beds (Q1 FY27)
p. 4
“During the quarter, we added 121 operational beds across the network, including 61 beds in the South cluster, 27 beds in West and 26 beds in East cluster and 7 beds in our Kenya unit.”
Manish Mattoo, page 4 of the filed PDF · View the filing
North Bangalore new patient registrations: over 550 (Q1 FY27)
p. 4
“In the very first quarter, the hospital recorded over 550 new patient registrations, more than 300 admissions.”
Manish Mattoo, page 4 of the filed PDF · View the filing
Capex: INR750 million (Q1 FY27)
p. 9
“We have incurred a capex of approximately INR750 million.”
Sanjeev Kumar, page 9 of the filed PDF · View the filing
Growth capex: INR35 crore (Q1 FY27)
p. 9
“And as far as the split is concerned, we have incurred almost INR35 crore on account of growth capex and almost INR40 crore in terms of the maintenance capex.”
Sanjeev Kumar, page 9 of the filed PDF · View the filing
Debt repayment from rights issue: INR170 crore
p. 5
“As you see that the interest cost has come down during this quarter because of the proceeds that we have raised from the right issue that has been used for the purpose of repayment of some of the debt almost amounting to INR170 crore.”
Sanjeev Kumar, page 5 of the filed PDF · View the filing
CGHS/price capping impact on top line: 1.5% (Q1 FY27)
p. 6
“So the impact in Q1 has been about 1.5% on our top line.”
Manish Mattoo, page 6 of the filed PDF · View the filing
Operating cash flow before working capital changes: ~INR125 crore (Q1 FY27)
p. 11
“We almost had an operating cash flow before the working capital changes of ~INR125 crore”
Sanjeev Kumar, page 11 of the filed PDF · View the filing
Net cash flow from operations: INR70 crore (Q1 FY27)
p. 12
“Yes, it will be approximately INR70 crore from operations.”
Sanjeev Kumar, page 12 of the filed PDF · View the filing
Marketing spend as percentage of sales: 2.9% (Q1 FY27)
p. 13
“it is gone up by 20% vis-a-vis last year quarter, it is today at 2.9% of our sales.”
Manish Mattoo, page 13 of the filed PDF · View the filing
Centers with record quarterly revenue: 16 out of 25 (Q1 FY27)
p. 3
“More importantly, growth was broad-based with 16 out of our 25 centers, excluding North Bangalore, delivering their highest ever quarterly revenues, reflecting sustained patient demand and improving execution across our hospitals.”
Manish Mattoo, page 3 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Bed additions — 65 beds in FY27, 520 beds in FY28 and FY29, 230 beds in FY30 · FY27-FY30
stated firmly by Manish Mattoo
p. 4
“Looking ahead, we have plans to add additional 65 beds in FY27, 520 beds in FY28 and FY29, and 230 beds in FY30.”
Manish Mattoo, page 4 of the filed PDF · View the filing
Revenue growth — mid-teens
stated firmly by Manish Mattoo
p. 6
“So, we remain confident of delivering a mid-teens growth from the existing centers and including the new ones that we are building through the greenfield and brownfield expansion.”
Manish Mattoo, page 6 of the filed PDF · View the filing
EBITDA margin — 24%, 25% · next few years
stated as an aspiration by Manish Mattoo
p. 11
“I think, we are in a very good position to meet the 24%, 25% EBITDA margins in the next few years.”
Manish Mattoo, page 11 of the filed PDF · View the filing
EBITDA margin — 21%, 22% · next 2 years
stated conditionally by Manish Mattoo
p. 13
“So I said in the next 2 years, we are looking at a 21%, 22% EBITDA margin.”
Manish Mattoo, page 13 of the filed PDF · View the filing
EBITDA margin — 25% · next 4 to 5 years
stated conditionally by Manish Mattoo
p. 13
“For the next 4 to 5 years, we are confident of clocking the 25% margin number.”
Manish Mattoo, page 13 of the filed PDF · View the filing
Marketing spend as percentage of sales — 2.5% to 2.6% · long term
stated firmly by Manish Mattoo
p. 13
“It will be in the 2.5% to 2.6%.”
Manish Mattoo, page 13 of the filed PDF · View the filing
North Bangalore hospital breakeven — monthly breakeven · this year
stated firmly by Sanjeev Kumar
p. 10
“But just to add to that, what we expect is the kind of response that we have got. Initially in our North Bangalore facility, we certainly expect to have a monthly breakeven in this year.”
Sanjeev Kumar, page 10 of the filed PDF · View the filing
North Bangalore utilization — 60%-65% optimal utilization · third to fourth year of operation
stated conditionally by Manish Mattoo
p. 10
“I think the optimal utilization of 60%-65% we should be anywhere between third to fourth year of operation.”
Manish Mattoo, page 10 of the filed PDF · View the filing
Greenfield project in Whitefield — operationalize · end of FY28
stated conditionally by Manish Mattoo
p. 5
“So I think the likelihood of the first one to operationalize is somewhere at the end of FY28 and the other one in the subsequent year.”
Manish Mattoo, page 5 of the filed PDF · View the filing
ESOP charge disclosure — quarter 2
stated firmly by Manish Mattoo
p. 6
“And on the second question, the ESOP policy is undergoing final stages of approval, and that charge will be evaluated basis the grand and its impact on company's P&L will be assessed and reported in quarter 2.”
Manish Mattoo, page 6 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said hospitals earning more than INR10 crore per month grew from 4 to 7, while the INR5-10 crore bucket shrank from 14 to 11.
Answered by Manish Mattoo
Asked by Sumit Gupta: How did revenue buckets by monthly revenue size perform this quarter?
p. 5
“the bucket with more than INR10 crore per month revenue we have got from last year 4 hospitals, we moved to 7 hospitals.”
Manish Mattoo, page 5 of the filed PDF · View the filing
Management believes the peak EBITDA loss has been reached this quarter and expects losses to decline in subsequent quarters.
Answered by Manish Mattoo
Asked by Aditya Chheda: What is the outlook on losses from the North Bangalore greenfield facility for FY27?
p. 6
“So as I think most of the costs have been built in, I feel we have reached the peak EBITDA loss in this quarter.”
Manish Mattoo, page 6 of the filed PDF · View the filing
Management said the impact was about 1.5% on top line but was margin accretive.
Answered by Manish Mattoo
Asked by Aditya Chheda: What was the impact of discontinuing certain chemo drugs on revenue?
p. 6
“So the impact in Q1 has been about 1.5% on our top line.”
Manish Mattoo, page 6 of the filed PDF · View the filing
Management described work on manpower and fixed costs using automation and data analytics, alongside patient experience and productivity initiatives.
Answered by Manish Mattoo
Asked by Jyothish Vijayan: What cost optimization initiatives are underway?
p. 7
“See, on the cost side, we see there is an opportunity across all the cost line items today. And the work is happening both on manpower costs and other fixed costs across centers.”
Manish Mattoo, page 7 of the filed PDF · View the filing
Management said Q1 capex was INR750 million split between growth and maintenance, with full-year maintenance capex expected around INR100 crore.
Answered by Sanjeev Kumar
Asked by Devang Patel: What is the capex spend for Q1 and full year maintenance capex?
p. 9
“So, the maintenance capex is likely to be approximately INR100 crore .”
Sanjeev Kumar, page 9 of the filed PDF · View the filing
Management said existing facilities can manage utilization up to 75-80%.
Answered by Manish Mattoo
Asked by Devang Patel: What utilization level can the existing Southern cluster reach without affecting growth?
p. 9
“So, the existing facilities can manage utilization level up to 75%, 80%.”
Manish Mattoo, page 9 of the filed PDF · View the filing
Management expressed confidence in reaching 24-25% EBITDA margins in the coming years.
Answered by Manish Mattoo
Asked by Rajat Srivastava: Can HCG reach a 23-25% margin level at the consolidated level in 2-3 years?
p. 11
“I think, we are in a very good position to meet the 24%, 25% EBITDA margins in the next few years.”
Manish Mattoo, page 11 of the filed PDF · View the filing
Management said more than 50% of centers are now in the 20%+ margin range.
Answered by Manish Mattoo
Asked by Rajat Srivastava: How many of the 25 hospitals are close to 25% margin level?
p. 11
“About 50% of our centers today, more than that actually, are in that range of 20%+.”
Manish Mattoo, page 11 of the filed PDF · View the filing
Management reported roughly INR125 crore operating cash flow before working capital changes and INR70 crore net cash flow from operations.
Answered by Sanjeev Kumar
Asked by Rajat Srivastava: What was the operating cash generation this quarter?
p. 11
“We almost had an operating cash flow before the working capital changes of ~INR125 crore”
Sanjeev Kumar, page 11 of the filed PDF · View the filing
Management reiterated long-term aspiration of reaching 24-25% margins, with 21-22% expected in 2 years.
Answered by Manish Mattoo
Asked by Jyothish Vijayan: What is the sustainable EBITDA margin range over the next 2-3 years?
p. 13
“See we have already stated our long-term aspiration is to get past that 21%, 22% and reach the 24%, 25% EBITDA margins.”
Manish Mattoo, page 13 of the filed PDF · View the filing
Management cited payor mix improvement, clinical/technology investment, operating leverage, and reduction of North Bangalore losses as key levers.
Answered by Manish Mattoo
Asked by Vedant Nilekar: What are the levers for margin expansion over the next 4-5 years?
p. 14
“So the big piece will come from improvement in our payor mix. That is the biggest lever, and we have already seen that happen consistently over the last couple of quarters.”
Manish Mattoo, page 14 of the filed PDF · View the filing
Risks flagged
Institutional business decline in West cluster moderated overall growth
p. 4
“Furthermore, institutional business in West cluster declined by more than 4% year-on-year, which moderated overall revenue growth of the cluster.”
Manish Mattoo, page 4 of the filed PDF · View the filing
Lower contribution from high-value low-margin therapies affected ARPP
p. 3
“ARPP improvement driven by favourable payor mix, partly offset by changes in case mix, including a lower contribution from high-value low-margin therapies.”
Manish Mattoo, page 3 of the filed PDF · View the filing
Reduction in scheme/immunotherapy business reduced value growth in West cluster
p. 10
“So as far as West is concerned, the growth which we may call the moderated growth, is largely on account of some of the reduction on account of the scheme business which is largely low margin immunotherapies, and that has largely impacted the value growth.”
Sanjeev Kumar, page 10 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.